

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

9

Complete if Known

Application Number	09/883,033
Filing Date	June 15, 2001
First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
Group Art Unit	1623
Examiner Name	Howard V. Owens, Jr.
Attorney Docket Number	06171.105026 (IDX 1005 US)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear
		Number	Kind Code (if known)			
		4,916,122		Chu	04-10-1990	
		4,957,924		Beauchamp	09-18-1990	
		5,149,794		Yatvin et al.	09-22-1992	
		5,190,926		Chu	03-02-1993	
		5,194,654		Hostetler et al.	03-16-1993	
		5,223,263		Hostetler et al.	06-29-1993	
		5,256,641		Yatvin et al.	10-01-2693	
		5,411,947		Hostetler et al.	05-02-1995	
		5,463,092		Hostetler et al.	10-31-1995	
		5,539,116		Liotta	07-23-1996	
		5,543,389		Yatvin et al.	08-06-1996	
		5,543,390		Yatvin et al.	08-06-1996	
		5,543,391		Yatvin et al.	08-06-1996	
		5,554,728		Basava et al.	09-10-1996	
		5,559,101		Weis et al.	09-24-1996	
		5,565,438		Chu	10-15-1996	
		5,567,688		Chu	10-22-1996	
		5,587,362		Chu	12-24-1996	
		5,939,402		Weis et al.	08-17-1999	
		6,025,335		Weis et al.	02-15-2000	
		6,194,391		Schinazi et al.	02-27-2001	
		6,245,749		Schinazi et al.	06-12-2001	
		6,297,222	B1	von Borstel et al.	10-02-2001	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **9**

Complete if Known

Application Number	09/883,033
Filing Date	June 15, 2001
First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
Group Art Unit	1623
Examiner Name	Howard V. Owens, Jr.
Attorney Docket Number	06171.105026 (IDX 1005 US)

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number	Kind Code ² (if known)				
		WO	89/02733		University of California	04-06-1989		
		WO	89/03838	A1	Pro-neuron, Inc.	05-05-1989		
		WO	90/00555		Vical, Inc.	01-25-1990		
		WO	91/16920		Vical, Inc.	11-14-1991		
		WO	91/18914		Vical, Inc.	12-12-1991		
		WO	91/19721		Glazier	12-26-1991		
		WO	92/01138		Yatvin	01-20-1994		
		WO	92/08727					
		WO	92/15308		Wellcome	09-17-1992		
		WO	92/18517		Yale et al.	10-29-1992		
		WO	93/00910		Vical, Inc.	01-21-1993		
		WO	94/20523		Burroughs Wellcome	09-15-1994		
		WO	94/26273		Hostetler	11-24-1994		
		WO	94/29331		Sloan-Kettering Inst. for Cancer Research	12-22-1994		
		WO	95/07086					
		WO	96/11204		Matthes & Von Jenta-Lipinski	04-18-1996		
		WO	96/13512		Genencor	05-09-1996		
		WO	96/15132		University of California	05-23-1996		
		WO	96/40164		Emory University	12-19-1996		
		WO	98/15563		Pankiewicz, K.W. et al	10-09-1997		
		EP	0 355 131	B1	Pro-neuron, Inc.	09-04-1996		
		EP	0 352 248		Medivir Aktiebolag	01-24-1990		
		EP	0 350 287		Vical, Inc.	02-10-1990		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/883,033
Sheet		3	of	9	Filing Date June 15, 2001
					First Named Inventor Jean-Pierre Sommadossi <i>et al.</i>
					Group Art Unit 1623
					Examiner Name Howard V. Owens, Jr.
					Attorney Docket Number 06171.105026 (IDX 1005 US)

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Office ³	Number	Kind Code ² (if known)				
		EP	0 494 119		BioChem Pharma	07-08-1992		
		JP	06-293645		Saneyoshi et al.	10-21-1994		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
		ARNER and ERIKSSON, "Mammalian Deoxyribonucleoside Kinases," <u>Pharm. Ther.</u> , 1995, 67(2), 155-186.	
		BERK et al., "A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria," <u>J Biol Chem</u> , 1973, 248, 2722-2729.	
		BESTWICK et al., "Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells," <u>J Biol Chem</u> , 1982, 257, 9300-9304.	
		BLOCH, et al. "The Role Of The 5'-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase." <u>J. Med. Chem.</u> 10(5), 908-12 (September 1967).	
		BRIDGES et al., "Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria," <u>J. Biol. Chem.</u> February 19, 1999, 274(8), 4620-4625.	
		BRIDGES et al., "Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs," <u>Proc. Am. Assoc. Cancer Res.</u> , March 1997, 38, 414.	
		BRIDGES et al., "Inhibition of Mammalian DNA Polymerase-Associated 3' to 5' Exonuclease Activity by 5'-Monophosphates of 3'-Azido-3'-Deoxythymine and 3'-Amino-3'-Deoxythymidine," <u>Biochemical Pharmacology</u> , 1993, 45(8), 1571-1576.	
		BRYANT et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," <u>Antimicrobial Agents and Chemotherapy</u> , 45(1), 229-235 (January 2001).	
		CHANG et al., "Biochemical Pharmacology of (+)- and (-)-2',3'-Dideoxy-3'-thiacytidine as Anti-hepatitis B Virus Agents," <u>J Biol Chem</u> , November 5, 1992, 267(31), 22414-22420.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/883,033
				Filing Date	June 15, 2001
				First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
Sheet	4	of	9	Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
		CHANG, et al., "Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (-)-2',3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," <i>Journal of Biological Chemistry</i> , Volume 267(20), 13938-13942 (July 15, 1992).	
		CHARIOT et al., "Zidovudine-induced mitochondrial disorder with massive liver steatosis myopathy, lactic acidosis, and mitochondrial DNA depletion," <i>J. Hepatology</i> , 1999, 30, 156-160.	
		CHEN et al., "Characterization of Pyrimidine Deoxyribonucleoside Kinase (Thymidine Kinase) and Thymidylate Kinase as a Multifunctional Enzyme in Cells Transformed by Herpes Simplex Virus Type 1 and in Cells Infected with Mutant Strains of Herpes Simplex Virus," <i>J Virol</i> , June 1979, 30, 942-945.	
		CHEN et al., "Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-human Immunodeficiency Virus Compound 2',3'-Dideoxycytidine," <i>J Biol Chem</i> , 1989, 264, 11934-11937.	
		CHEN et al., "The Role of Cytoplasmic Deoxycytidine Kinase in the Mitochondrial Effects of the Anti-human Immunodeficiency Virus Compound 2',3'-Dideoxycytine," <i>J Biol Chem</i> , February 15, 1992, 267(5), 2856-2859.	
		CUI et al., "Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells," <i>J. of Pharmacology and Experimental Therapeutics</i> , 1997, 280(3), 1228-1234.	
		DAVIS et al., "In Situ Localization of Mitochondrial DNA Replication in Intact Mammalian Cells," <i>J Cell Biol</i> , 1996, 135, 883-893.	
		DAVISSON, et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," <i>J. Org. Chem.</i> , 52(9), 1794-1801 (1987)	
		DOONG et al., "Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues," <i>Proc. Natl. Acad. Sci.</i> , October 1991, 88, 8495-8499.	
		DU et al, Synthesis, "Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides," <i>J. of Med. Chem.</i> , (40)19, 2991-2993 (September 12, 1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/883,033	
			Filing Date	June 15, 2001	
			First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>	
			Group Art Unit	1623	
			Examiner Name	Howard V. Owens, Jr.	
Sheet	5	of	9	Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DUTSCHMAN et al., "Metabolism of 2',3'-dideoxy-2',3'-didehydro-β-L(-)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Humna Immunodeficiency Virus β-D-(+) Nucleoside Analogs In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , July 1998, 42(7), 1799-1804.	
		FURMAN, et al., "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , 36(12) 2686-2692 (December 1992).	
		GLONEK, et al. "Full anhydrization of methylenediphosphonic acid and of phosphoric acids by a carbodiimide" <i>Inorg.Chem.</i> , 1975 Vol. 14 (7); 1597-602.	
		GOSSELIN, G. et al. "Synthesis and Antiviral Evaluation of β-L-Xylofuranosyl Nucleosides of the Five Naturally Occuring Nucleic Acid Bases", <i>Journal of Heterocyclic Chemistry</i> , 1993, 30 (Oct.-Nov.), 1229-1233.	
		HERNANDEZ-SANTIAGO et al., "Pharmacology of β-L-Thymidine and β-L-2'-Deoxycytidine in HepG2 Cell and Primary Human Hepatocytes: Relevance to Chemotherapeutic Efficacy against Hepatitis B Virus," <i>Antimicrobial Agents and Chemotherapy</i> , June 2002, 46(6), 1728-1733.	
		HOARD, et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," <i>J. Am. Chem. Soc.</i> , 87(8), 1785-1788 (1965).	
		HOLY. "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides of the Pyrimidine Series," <i>Collect. Czech. Chem. Commun.</i> (1972), 37(12), 4072-87.	
		HOSTETLER, K.Y., et al. "Greatly Enhanced Inhibition Of Human Immunodeficiency Virus Type 1 Replication In CEM And HT4-6C Cells By 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, A Lipid Prodrug Of 3'-Deoxythymidine." (September 1992) <i>Antimicrob Agents Chemother.</i> 36:2025-2029.	
		HOSTETLER, K.Y., et al. "Synthesis And Antiretroviral Activity Of Phospholipid Analogs Of Azidothymidine And Other Antiviral Nucleosides." (April 15, 1990) <i>J. Biol Chem.</i> 265(11):6112-7.	
		IMAI et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." <i>J. Org. Chem.</i> , 34(6), 1547-1550 (June 1969).	
		JONES, R. et al., "Mini Review: Nucleotide prodrugs," <i>Antiviral Research</i> , 27, 1-17 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	09/883,033
Filing Date	June 15, 2001
First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
Group Art Unit	1623
Examiner Name	Howard V. Owens, Jr.
Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JUROVČIK and HOLY "Metabolism of pyrimidine L-nucleosides," <i>Nucleic Acids Research</i> , August 1976, 3(8), 2143-2153.	
		KORBA <i>et al.</i> , "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Res.</i> , 15:217 (1991).	
		KRAYEVSKY and CHERNOV, "Can a Substrate Enantiomer Be a Substrate for the Same Enzyme?," <i>Molecular Biology</i> , 1996, 30(5), 585-591.	
		KRAYEVSKY and CHERNOV, "Should the Asymmetric of Enzymatic Active Centers Always Correlate with the Asymmetry of their Substrates?," <i>J. of Biochemical Structure & Dynamics</i> , 1996, 14(2), 225-230.	
		KUCERA, L.S., <i>et al.</i> , "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation." <i>AIDS Res Hum Retroviruses</i> , 6:491-501 (May 1990).	
		LABENZ <i>et al.</i> , "Analysis of the TK Enzyme Complex Induced by HSV Types 1 and 2 by Means of Isoelectric Focusing and Polyacrylamide Gel Electrophoresis," <i>Arch Virol</i> , 1982, 71, 235-249.	
		LIN <i>et al.</i> , "Design and Synthesis of 2',3'-Dideoxy-2', 3'-dihydro-β-L-cytidine (β-L-Fd4C), Two Exceptionally Potent Inhibitors of Human HBV and Potent Inhibitors of HIV <i>In Vitro</i> ," <i>J. Med. Chem.</i> , 39(9), 1757-1759 (April 26, 1996).	
		LIN <i>et al.</i> , "Synthesis and Biological Evaluation of 2',3'-Dideoxy-L-pyrimidine Nucleosides as Potential Antiviral Agents against HIV and HBV," <i>J. Med. Chem</i> , 1994, 97, 798-803.	
		LIN <i>et al.</i> , "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," <i>Tetrahedron Letters</i> , Vol. 51(4), 1055,1068 (1995).	
		MAGA <i>et al.</i> , "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," <i>Biochem. J.</i> , 294(2), 381-385 (September 1, 1993).	
		MANSOUR <i>et al.</i> , "Stereochemical Aspects of the Anti-HCMV Activity of Cytidine Nucleoside Analogues," <i>Antiviral Chemistry & Chemotherapy</i> , 6(3), 138-142 (1995).	
		Morris S. Zedeck <i>et al.</i> <i>Pseudomonas testosteroni</i> , <i>Mol. Phys.</i> (1967), 3(4), 386-95.	
		NAKAYAMA, C., <i>et al.</i> , "Synthetic Nucleosides and Nucleotides. XX. Synthesis of Various 1-β-Xylofuranosyl-5-Alkyluracils and Related Nucleosides." <i>Nucleosides, Nucleotides</i> , 1, 139-146 (1982)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/883,033
		Filing Date	June 15, 2001
		First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
		Group Art Unit	1623
		Examiner Name	Howard V. Owens, Jr.
		Attorney Docket Number	06171.105026 (IDX 1005 US)
(use as many sheets as necessary)			
Sheet	7	of	9

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
		NORBECK, <i>Tetrahedron Letters</i> , 30 (46), 6246 (1989)	
		PANKIEWICZ, et al. "Efficient synthesis of methylenebis(phosphonate) analogues of P1,P2-disubstituted pyrophosphates of biological interest. (1997-04-15), 119, 3691-3692.	
		PANKIEWICZ, et al. "Synthesis of methylenebis(phosphonate) analogs of ADP Ribose" Collect. Czech. Chem. Commun. (1996-09- 23), 61; S92-S-95.	
		PAN-ZHOU et al., "Differential Effects of Antiretroviral Nucleoside Analogs on Mitochondrial Function in HepG2 Cells," <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, 44(3), 496-503.	
		PLACIDI et al., "Cellular pharmacology of β -L-thymidine and β -L-2'-deoxycytidine in HepG2 cells and primary rat, monkey and human hepatocytes," 3 rd Int. Conf. Ther. Vir. Hepatitis, abstr. A122, 1999 [<i>Antivir. Ther.</i> 4, Suppl. 4].	
		ROBINS, "Selective Deoxygenation and Modification at C2' of Nucleosides," <i>Nucleic Acids Research Symposium Series</i> , Vol. 11, Pages 1-4, Kyoto, Japan, November 24-26, 1982, A.E. Pritchard (ed.), IRL Press, Ltd., Oxford, England, 1982;	X
		ROBINS, M. J. et al. "Purine nucleosides. XXIX. The synthesis of 2'-deoxy-L-adenosine and 2'-deoxy-L-guanosine and their alpha anomers." <i>J. Org. Chem.</i> March 1970, 35, 636-639.	
		ROBINS, M.J., et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides." <i>J. Am. Chem. Soc.</i> 105, 4059-4065 (1983).	
		SANEYOSHI, M., et al., "Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines." <i>Chem. Pharm. Bull.</i> , 27, 2518-2521 (1979).	
		SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl] Cytosine," <i>Antimicrobial Agents and Chemotherapy</i> , 36(11), 2423-2431 (1992).	
		SCHINAZI, et al., "Effect of Combinations of Acyclovir with Vidarabine or its Monophosphate on Herpes Simplex Viruses in Cell Culture and in Mice," <i>Antimicrobial Agents and Chemotherapy</i> , 22(3), 499, (1982).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/883,033
		Filing Date	June 15, 2001
		First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
		Group Art Unit	1623
		Examiner Name	Howard V. Owens, Jr.
		Attorney Docket Number	06171.105026 (IDX 1005 US)
Sheet	8	of	9

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SHUTO, S., et al. "A facile one-step synthesis of 5'-phosphatidyl nucleosides by an enzymatic two-phase reaction." <i>Tetrahedron Letters</i> . 28. 199-202 (1987).	
		SODERLUND and ARNER, "Mitochondrial versus Cytosolic Activities of Deoxyribonucleoside Salvage Enzymes," <i>Purine and Pyrimidine Metabolism in Man VIII</i> , A. Shota & M. Taylor (ed.), Plenum Press, New York, 1995, 201-204.	
		SPADARI et al., "L-Thymidine is Phosphorylated by Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth," <i>J. Med. Chem.</i> (1992), 35(22), 4214-4220.	
		TYRSTED et al. "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxy-adenosine and structurally related nucleoside analogs." <i>Biochim. Biophys. Acta.</i> (February 26, 1968), 155(2), 619-22.	
		VERRI et al. "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents." <i>Molecular Pharmacology</i> . (January 1997), 51(1), 132-138.	
		VERRI et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," <i>Biochem. J.</i> (1997), 328(1), 317-320 (November 15, 1997).	
		von JANTA-LIPINSKI et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified β -2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular DNA Polymerases α , β , γ , δ , and ϵ Nor HIV-1 Reverse Transcriptase," <i>J. Medicinal Chemistry</i> , 41(12), 2040-2046 (June 4, 1996).	
		Wang, S., Montelaro, R., Schinazi, R.R., Jagerski, B. and Mellors, J.W.: Activity of nucleoside and non-nucleoside reverse transcriptase inhibitors (NNRTI) against equine infectious anemia virus (EIAV). First National Conference on Human Retroviruses and Related Infections, Washington, DC, Dec. 12-16, 1993	
		ZEDECK et al. "Pseudomonas testosteroni," <i>Mol. Phys.</i> (1967), 3(4), 386-95.	
		ZHANG, W., et al. "Removal of Silyl Protecting Groups from Hydroxyl Functions with Ammonium Fluoride in Methanol." <i>Tetrahedron Letter.</i> , 33, 1177-1180 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/883,033
				Filing Date	June 15, 2001
				First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
Sheet	9	of	9	Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
		ZHU et al., "Anti-Hepatitis B Virus Activity and Metabolism of 2',3'-dideoxy-2',3'-didehydro-β-L-(-)-5-Fluorocytidine," <i>Antimicrobial Agents and Chemotherapy</i> , July 1998, 42(7), 1805-1810.	
		ZHU et al., "Incorporation of Nucleoside Analogs into Nuclear or Mitochondrial DNA Is Determined by the Intracellular Phosphorylation Site," <i>J Biol Chem</i> , 2000, 275(35), 26727-26731.	
		ZHU et al., "Inhibition of Replication of Hepatitis B Virus by Cytallene In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , August 1997, 41(8), 1755-1760.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.